Madurai News

Dravet Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Dravet Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 16
19:26 2023
Dravet Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Dravet Syndrome Pipeline Insights
DelveInsight’s ‘Dravet Syndrome Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Dravet Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dravet Syndrome pipeline domain.

DelveInsight’s Dravet Syndrome Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Dravet Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dravet Syndrome pipeline domain.

Key Takeaways from the Dravet Syndrome Pipeline Report

  • Over 15+ Dravet Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Dravet Syndrome market would significantly increase market revenue. 
  • Leading Dravet Syndrome companies developing novel drug candidates to improve the Dravet Syndrome treatment landscape include Takeda, Eisai, Stoke Therapeutics, and others.
  • Promising Dravet Syndrome pipeline therapies in various stages of development include Soticlestat, Larcaserin, STK-001, and others.

Dravet Syndrome Overview

Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems. 

Dravet Syndrome Foundation, states that DS is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. 

Dravet Syndrome Pipeline Analysis: Drug Profile

Lorcaserin: Eisai

Lorcaserin, a serotonin 2C receptor agonist is being developed by Eisai. Lorcaserin works by selectively activating serotonin 2C receptors in the brain, through the activation GABAergic inhibitory interneuron, expected to suppress seizure of Dravet syndrome by increasing synaptic suppression from GABAergic. Although approval for the obesity indication has been voluntarily withdrawn, due to the request from Dravet syndrome patient groups, the extended access program has been continued in the United States, and the Phase III study is underway for this indication. The US FDA granted ODD for the treatment of Dravet Syndrome. Currently, the drug is in Phase III trial. 

Discover more about the emerging Dravet Syndrome drugs @ Dravet Syndrome Treatment Drugs

Dravet Syndrome Key Companies

  • Takeda
  • Eisai
  • Stoke Therapeutics
  • And others

Dravet Syndrome Pipeline Therapies

  • Soticlestat
  • Larcaseri
  • STK-001
  • And others

Dravet Syndrome Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Dravet Syndrome Pipeline Report 

  • Coverage: Global 
  • Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeutics, and others
  • Key Dravet Syndrome Pipeline Therapies: Soticlestat, Larcaserin,STK-001, and others

Find out more about the Dravet Syndrome treatment options in development @ Dravet Syndrome Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Download a sample report @ Dravet Syndrome Clinical Trials

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/